Surgical Innovation Through Lung Function–Preserving Surgical Procedures

Abstract

Lung function–preserving surgical procedures represent a significant advancement in thoracic surgery, prioritizing the maintenance of pulmonary reserve while effectively treating pulmonary diseases, particularly early-stage lung cancer and benign lesions. This review critically evaluates the epidemiological context, underlying mechanisms, risk stratification, clinical presentation, diagnostic pathways, and contemporary management strategies. Emphasis is placed on recent innovations, evidence-based recommendations, and the clinical implications for optimizing patient outcomes through precision surgery and multidisciplinary care.

Introduction

In the era of personalized medicine and minimally invasive intervention, preserving lung function during thoracic surgery has become a pivotal goal. Traditional resections, such as pneumonectomy and lobectomy, while effective in disease control, often compromise long-term respiratory capacity. The evolution toward lung function–preserving procedures, including segmentectomy, wedge resection, and bronchoplastic techniques, has been driven by improved imaging, better understanding of tumor biology, and the desire to reduce morbidity, especially in patients with limited pulmonary reserve. This article explores the scientific rationale, clinical execution, and emerging evidence surrounding these innovative surgical approaches.

Epidemiology / Disease Burden

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non–small cell lung cancer (NSCLC) accounting for approximately 85% of cases. An increasing number of patients present with early-stage disease due to low-dose CT screening, many of whom are elderly or have comorbidities that limit their surgical candidacy. Chronic obstructive pulmonary disease (COPD) coexists in over 40% of lung cancer patients, compounding the need for lung function–sparing interventions. Similarly, benign pulmonary lesions and localized infections require surgical management that minimizes functional loss, underscoring the broad applicability and growing demand for function-preserving procedures.

Pathophysiology

Lung resection, whether anatomical or non-anatomical, induces a reduction in lung volume proportional to the extent of tissue removed. Traditional lobectomy or pneumonectomy can precipitate postoperative respiratory insufficiency, particularly in individuals with pre-existing lung disease. Segmentectomy and wedge resection, by contrast, aim to excise diseased parenchyma while preserving maximal functional lung units. Bronchoplastic and sleeve resections maintain airway continuity, preventing loss of ventilated segments. The pathophysiological basis for these techniques hinges on maintaining perfusion-ventilation relationships, minimizing dead space, and preserving the elastic recoil necessary for effective gas exchange.

Risk Factors

Risk stratification for lung resection incorporates age, baseline pulmonary function tests (PFTs), cardiopulmonary comorbidities, smoking history, and tumor location. Patients with forced expiratory volume in one second (FEV1) or diffusing capacity for carbon monoxide (DLCO) less than 60% predicted are at heightened risk for postoperative complications. Frailty, malnutrition, and poor functional status further increase surgical risk. Understanding these risk factors informs the selection of patients most likely to benefit from lung function–preserving procedures, reducing perioperative morbidity and optimizing recovery.

Clinical Features

Patients eligible for lung function–preserving surgery may present with localized pulmonary nodules, ground-glass opacities, or early-stage malignancies detected through screening. Symptoms are often absent or non-specific, including cough, mild dyspnea, or incidental radiographic findings. In benign disease, clinical features reflect the nature of the underlying pathology—such as recurrent infections or hemoptysis in bronchiectasis. Comprehensive assessment, including functional status and comorbidities, is essential for appropriate surgical planning.

Diagnosis

Diagnosis is established through high-resolution computed tomography (CT), positron emission tomography (PET) for oncologic staging, and tissue diagnosis via minimally invasive biopsy techniques or navigational bronchoscopy. Pulmonary function testing quantifies baseline reserve, guiding the extent of feasible resection. Three-dimensional imaging and virtual bronchoscopy facilitate preoperative planning, allowing precise mapping of segmental anatomy and identification of critical vascular and bronchial structures. Multidisciplinary tumor boards play a crucial role in integrating diagnostic findings for individualized treatment planning.

Treatment & Management

Lung function–preserving surgery encompasses a spectrum of procedures. Segmentectomy, the anatomic resection of one or more bronchopulmonary segments, is increasingly recognized as oncologically equivalent to lobectomy for select small (<2 cm), peripheral NSCLC. Wedge resection, a non-anatomic excision, is reserved for frail patients or benign lesions. Sleeve resection and bronchoplasty maintain airway integrity without sacrificing entire lobes. Video-assisted thoracoscopic surgery (VATS) and robotic platforms have further minimized surgical trauma, shortened hospital stay, and expedited recovery. Perioperative care focuses on optimizing respiratory function, early mobilization, and vigilant monitoring for complications such as air leak or pneumonia.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable advances in surgical technology and technique. Robotic-assisted thoracic surgery (RATS) offers superior dexterity, visualization, and precision, facilitating complex segmentectomies and sleeve resections. Intraoperative imaging with indocyanine green (ICG) fluorescence delineates intersegmental planes, ensuring adequate margins while preserving healthy parenchyma. Enhanced recovery after surgery (ERAS) protocols, incorporating minimally invasive anesthesia, multimodal analgesia, and early ambulation, have reduced perioperative morbidity. Ablative therapies, such as radiofrequency ablation and stereotactic body radiotherapy (SBRT), provide alternative options for non-surgical candidates, further expanding the therapeutic armamentarium.

Guideline Recommendations

Current guidelines, including those from the American College of Chest Physicians (ACCP) and European Society of Thoracic Surgeons (ESTS), endorse segmentectomy for peripheral stage IA NSCLC (<2 cm) when negative margins and lymph node sampling can be ensured. Lobectomy remains standard for larger or central tumors. Preoperative assessment of pulmonary reserve is mandatory, with recommendations to avoid resection in patients with predicted postoperative FEV1 or DLCO below 30% predicted. Multidisciplinary evaluation is essential to individualize treatment, weighing oncologic efficacy against functional preservation. Adherence to evidence-based protocols is paramount to achieving optimal outcomes.

Conclusion

Lung function–preserving surgical procedures represent a paradigm shift in thoracic surgery, enabling effective disease management while safeguarding pulmonary reserve. Through meticulous patient selection, advanced surgical techniques, and adherence to guideline-driven care, clinicians can maximize benefits and minimize risks. Ongoing research and technological innovation promise to further refine these approaches, offering hope for improved quality of life and survival in patients with pulmonary disease. The future of thoracic surgery lies in integrating precision, safety, and individualized care to meet the complex needs of this diverse patient population.